Vassiliadi, D. A., Barber, T. (Thomas), Hughes, B. A., McCarthy, M. I., Wass, J. A. H., Franks, S., Nightingale, P., Tomlinson, J. W., Arlt, W. and Stewart, P. M.. (2009) Increased 5α-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism , Vol.94 (No.9). pp. 3558-3566. ISSN 0021-972x

Full text not available from this repository.

Abstract

Context: Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, anovulation, and susceptibility to the metabolic syndrome. Altered peripheral cortisol metabolism has been reported in PCOS, but also in simple obesity. Objective: The aim of the study was to describe cortisol metabolism and metabolic characteristics of a large PCOS cohort and to delineate the effect of obesity by comparison to body mass index (BMI)-matched controls. Design and Setting: We conducted an observational, cross-sectional study at outpatient clinics of two secondary/tertiary care centers. Patients or Other Participants: A total of 178 PCOS patients fulfilling Rotterdam criteria and 100 BMI-matched controls participated in the study. Intervention: The study included 24-h urine collection for steroid metabolite excretion and fasting blood samples, followed by an oral glucose tolerance test. Main Outcome Measures: We measured urinary steroid metabolites including glucocorticoids and androgens and the ratios reflecting enzymatic activities involved in peripheral cortisol and androgen metabolism, 5α-reductase, and 11β-hydroxysteroid dehydrogenase types 1 and 2. We also measured circulating levels of glucose, insulin, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and testosterone and calculated homeostasis model assessment. Results: Total androgen metabolites were higher in PCOS patients compared to BMI-matched controls (4,105 ± 2,047 vs. 2,532 ± 1,610 μg/24 h for the nonobese; 5,547 ± 2,911 vs. 2,468 ± 1,794 μg/24 h for the obese; both P < 0.001). Total glucocorticoid metabolites were higher in obese PCOS vs. controls (10,786 ± 3,852 vs. 8,834 ± 4,487 μg/24 h; P = 0.001). 5α-Reductase activity correlated with BMI, insulin levels, and homeostasis model assessment. Both obese and nonobese PCOS patients had higher 5α-reductase activity than controls (all P < 0.05). 11β-Hydroxysteroid dehydrogenase activities did not differ between PCOS and controls. Conclusions: PCOS is associated with enhanced androgen and cortisol metabolite excretion and increased 5α-reductase activity that cannot be explained by obesity alone. Increased adrenal corticosteroid production represents an important pathogenic pathway in PCOS.

Item Type:	Journal Article
Divisions:	Faculty of Medicine > Warwick Medical School > Metabolic and Vascular Health Faculty of Medicine > Warwick Medical School
Journal or Publication Title:	Journal of Clinical Endocrinology & Metabolism
Publisher:	Endocrine Society
ISSN:	0021-972x
Date:	2009
Volume:	Vol.94
Number:	No.9
Page Range:	pp. 3558-3566
Identification Number:	10.1210/jc.2009-0837
Status:	Peer Reviewed
Publication Status:	Published
URI:	http://wrap.warwick.ac.uk/id/eprint/43555

Request changes to a record

Actions (login required)

View Item